232 related articles for article (PubMed ID: 7677962)
1. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer.
Oesterling JE; Martin SK; Bergstralh EJ; Lowe FC
JAMA; 1993 Jan; 269(1):57-60. PubMed ID: 7677962
[TBL] [Abstract][Full Text] [Related]
2. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer.
Gleave ME; Coupland D; Drachenberg D; Cohen L; Kwong S; Goldenberg SL; Sullivan LD
Urology; 1996 May; 47(5):708-12. PubMed ID: 8650870
[TBL] [Abstract][Full Text] [Related]
3. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer.
Huncharek M; Muscat J
Cancer Invest; 1995; 13(1):31-5. PubMed ID: 7530590
[TBL] [Abstract][Full Text] [Related]
4. Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications.
Oesterling JE
Urol Clin North Am; 1993 Nov; 20(4):705-11. PubMed ID: 7505979
[TBL] [Abstract][Full Text] [Related]
5. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan.
Kosuda S; Yoshimura I; Aizawa T; Koizumi K; Akakura K; Kuyama J; Ichihara K; Yonese J; Koizumi M; Nakashima J; Fujii H
Cancer; 2002 Feb; 94(4):964-72. PubMed ID: 11920464
[TBL] [Abstract][Full Text] [Related]
6. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
[TBL] [Abstract][Full Text] [Related]
7. [Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].
Wang TY; Chen XP; Li XS; Jia Yx; Cheng J; Zhang JH; Cai L; Zhang Z; Gong K; He ZS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 44(4):528-34. PubMed ID: 22898839
[TBL] [Abstract][Full Text] [Related]
8. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase.
Wymenga LF; Boomsma JH; Groenier K; Piers DA; Mensink HJ
BJU Int; 2001 Aug; 88(3):226-30. PubMed ID: 11488734
[TBL] [Abstract][Full Text] [Related]
9. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients.
Lorente JA; Valenzuela H; Morote J; Gelabert A
Eur J Nucl Med; 1999 Jun; 26(6):625-32. PubMed ID: 10369948
[TBL] [Abstract][Full Text] [Related]
10. Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? A retrospective study.
Al-Ghazo MA; Ghalayini IF; Al-Azab RS; Bani-Hani I; Barham A; Haddad Y
Int Braz J Urol; 2010; 36(6):685-91; discussion 691-2. PubMed ID: 21176275
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer].
Kageyama Y; Kihara K; Kamata S; Nagahama K; Yonese J; Fukuda H; Tosaka A; Nagamatsu H; Ishizaka K; Tsujii T; Kitahara S; Morita T; Oshima H
Hinyokika Kiyo; 1996 Mar; 42(3):197-9. PubMed ID: 8619388
[TBL] [Abstract][Full Text] [Related]
12. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer.
Huncharek M; Muscat J
Abdom Imaging; 1996; 21(4):364-7. PubMed ID: 8661585
[TBL] [Abstract][Full Text] [Related]
13. [The relationship between the serum level of prostate specific antigen and bone and CT scans in the staging of the primary carcinoma of the prostate].
Hoefman E; Hulshof MC; de Reijke TM; Bruijnes E; Redekop WK; van Straalen JP
Ned Tijdschr Geneeskd; 1998 May; 142(20):1142-6. PubMed ID: 9623236
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen, Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan.
Ishizuka O; Tanabe T; Nakayama T; Kawakami M; Kinebuchi Y; Nishizawa O
Int J Urol; 2005 Aug; 12(8):728-32. PubMed ID: 16174046
[TBL] [Abstract][Full Text] [Related]
15. Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: feasibility in Asian population.
Lai MH; Luk WH; Chan JC
Urol Oncol; 2011; 29(3):275-9. PubMed ID: 19734069
[TBL] [Abstract][Full Text] [Related]
16. Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer?
Vijayakumar V; Vijayakumar S; Quadri SF; Blend MJ
Am J Clin Oncol; 1994 Oct; 17(5):432-6. PubMed ID: 7522394
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer.
Wolff JM; Bares R; Jung PK; Buell U; Jakse G
Urol Int; 1996; 56(3):169-73. PubMed ID: 8860738
[TBL] [Abstract][Full Text] [Related]
18. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
19. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.
Briganti A; Passoni N; Ferrari M; Capitanio U; Suardi N; Gallina A; Da Pozzo LF; Picchio M; Di Girolamo V; Salonia A; Gianolli L; Messa C; Rigatti P; Montorsi F
Eur Urol; 2010 Apr; 57(4):551-8. PubMed ID: 20034730
[TBL] [Abstract][Full Text] [Related]
20. Using prostate-specific antigen to eliminate the staging radionuclide bone scan.
Lee CT; Oesterling JE
Urol Clin North Am; 1997 May; 24(2):389-94. PubMed ID: 9126236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
